Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrika Mattson

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Scientific Reports|September 24, 2021
Quantitative assessment of sensitizing potency using a dose-response adaptation of GARDskinRobin Gradin, Andy Forreryd, Ulrika Mattson, et al.
Toxics|September 27, 2024
In Vitro Prediction of Skin-Sensitizing Potency Using the GARDskin Dose-Response Assay: A Simple Regression ApproachRobin Gradin, Fleur Tourneix, Ulrika Mattson, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 19, 2020
The GARDpotency Assay for Potency-Associated Subclassification of Chemical Skin Sensitizers-Rationale, Method Development, and Ring Trial Results of Predictive Performance and ReproducibilityRobin Gradin, Angelica Johansson, Andy Forreryd, et al.
Regulatory Toxicology and Pharmacology : RTP|March 7, 2024
GARD™skin and GARD™potency: A proof-of-concept study investigating applicability domain for agrochemical formulationsMarco Corvaro, Joseph Henriquez, Raja Settivari, et al.
Scientific Reports|February 2, 2020
A bispecific IgG format containing four independent antigen binding sitesAnne Ljungars, Torbjörn Schiött, Ulrika Mattson, et al.
Regulatory Toxicology and Pharmacology : RTP|March 9, 2024
GARDskin dose-response assay and its application in conducting Quantitative Risk Assessment (QRA) for fragrance materials using a Next Generation Risk Assessment (NGRA) frameworkShashikiran Donthamsetty, Andy Forreryd, Paul Sterchele, et al.
ALTEX|January 28, 2025
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assayIsabelle Lee, Andy Forreryd, Mihwa Na, et al.
JCI Insight|September 2, 2020
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulationMuchaala Yeboah, Charys Papagregoriou, Des C Jones, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Scientific Reports|September 24, 2021
Quantitative assessment of sensitizing potency using a dose-response adaptation of GARDskinRobin Gradin, Andy Forreryd, Ulrika Mattson, et al.
Toxics|September 27, 2024
In Vitro Prediction of Skin-Sensitizing Potency Using the GARDskin Dose-Response Assay: A Simple Regression ApproachRobin Gradin, Fleur Tourneix, Ulrika Mattson, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 19, 2020
The GARDpotency Assay for Potency-Associated Subclassification of Chemical Skin Sensitizers-Rationale, Method Development, and Ring Trial Results of Predictive Performance and ReproducibilityRobin Gradin, Angelica Johansson, Andy Forreryd, et al.
Regulatory Toxicology and Pharmacology : RTP|March 7, 2024
GARD™skin and GARD™potency: A proof-of-concept study investigating applicability domain for agrochemical formulationsMarco Corvaro, Joseph Henriquez, Raja Settivari, et al.
Scientific Reports|February 2, 2020
A bispecific IgG format containing four independent antigen binding sitesAnne Ljungars, Torbjörn Schiött, Ulrika Mattson, et al.
Regulatory Toxicology and Pharmacology : RTP|March 9, 2024
GARDskin dose-response assay and its application in conducting Quantitative Risk Assessment (QRA) for fragrance materials using a Next Generation Risk Assessment (NGRA) frameworkShashikiran Donthamsetty, Andy Forreryd, Paul Sterchele, et al.
ALTEX|January 28, 2025
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assayIsabelle Lee, Andy Forreryd, Mihwa Na, et al.
JCI Insight|September 2, 2020
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulationMuchaala Yeboah, Charys Papagregoriou, Des C Jones, et al.
Pageof 1